The early formation of Aß in the AD neurotoxic pathogenic cascade and the slowed memory decline found upon abolished Aβ production in BACE-1 knockout mice [2–5] suggest that BACE-1 may be a prime biological target for a disease-modifying therapeutic approach in AD [6–8]. This evidence concerns the gene BACE1 and Alzheimer disease.